NewAmsterdam's bid to revive Amgen cardio drug heads to Nasdaq in Frazier SPAC deal - Endpoints News
7/25/2022 12:00:00 AM2 years 9 months ago
by Kyle LaHucik
by Kyle LaHucik
Five years after Amgen buried its CETP cholesterol drug, a Dutch biotech with hundreds of millions in funding is headed to Wall Street to continue testing the therapy in Phase III trials. A month after spreading the news about securing $123 million upfront in…
Five years after Amgen buried its CETP cholesterol drug, a Dutch biotech with hundreds of millions in funding is headed to Wall Street to continue testing the therapy in Phase III trials. A month af… [+616 chars]
full article...